

Clerk of the House of Representatives Legislative Resource Center 135 Cannon Building Washington, DC 20515 http://lobbyingdisclosure.house.gov	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510 http://www.senate.gov/lobby
--	---

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name <input checked="" type="checkbox"/> Organization/Lobbying Firm <input type="checkbox"/> Self Employed Individual CVS Health	
2. Address Address1 <u>1275 Pennsylvania Avenue, NW</u> Address2 <u>Suite 700</u> City <u>Washington</u> State <u>DC</u> Zip Code <u>20004</u> Country <u>USA</u>	
3. Principal place of business (if different than line 2) City <u>Woonsocket</u> State <u>RI</u> Zip Code <u>02895</u> Country <u>USA</u>	
4a. Contact Name <u>Mrs. Shannon Penberthy</u>	b. Telephone Number <u>2027723504</u> c. E-mail <u>shannon.penberthy@cvshealth.com</u>
5. Senate ID# <u>302778-12</u>	
7. Client Name <u>CVS Health</u> <input checked="" type="checkbox"/> Self <input type="checkbox"/> Check if client is a state or local government or instrumentality	6. House ID# <u>394420000</u>

TYPE OF REPORT 8. Year 2018 Q1 (1/1 - 3/31) Q2 (4/1 - 6/30) Q3 (7/1 - 9/30) Q4 (10/1 - 12/31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report Termination Date _____ 11. No Lobbying Issue Activity

INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13	
<p>12. Lobbying</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$5,000 <input type="checkbox"/></p> <p>\$5,000 or more <input type="checkbox"/> \$ _____</p> <p>Provide a good faith estimate, rounded to the nearest \$10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p>13. Organizations</p> <p>EXPENSE relating to lobbying activities for this reporting period were:</p> <p>Less than \$5,000 <input type="checkbox"/></p> <p>\$5,000 or more <input checked="" type="checkbox"/> \$ <u>1,803,000.00</u></p> <p>14. REPORTING Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definitions only</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code</p>

Signature Digitally Signed By: Shannon Penberthy Date _____

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code PHA

16. Specific lobbying issues

Issues related to prescription drug abuse, medication adherence, generic drug approvals, biologic exclusivity periods, drug price transparency, and gag clauses.

H.R. 1316, The Prescription Drug Price Transparency Act of 2017
 S. 778/H.R. 1854, The Prescription Drug Monitoring Act of 2017
 S. 2460/H.R. 3528, The Every Prescription Conveyed Safely Act of 2017
 S. 892/H.R. 4408, The Opioid Addiction Prevention Act of 2017
 S. 2456 / H.R. 5311, The CARA 2.0 Act of 2018
 H.R. 4482, The Opioid Abuse Deterrence, Research, and Recovery Act of 2017
 S. 2553, The Know the Lowest Price Act of 2018
 S. 2554, The Patient Right to Know Drug Prices Act of 2018
 H.R. 5343, The Prescription Transparency Act of 2018

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Melissa	Schulman			<input type="checkbox"/>
Elizabeth	Brooks			<input type="checkbox"/>
Shannon	Penberthy			<input type="checkbox"/>
Ashli	Palmer			<input type="checkbox"/>
Tegan	Gelfand			<input type="checkbox"/>
Amy	Rosenbaum		Sr Advisor/Deputy Advisor to the President; Policy Director, Office of Speaker/Minority Leader; Sr Advisor, Committee on Education & the Workforce; Research Dir, Asst to Minority Leader; Staff Asst, Leg Asst, Leg Dir, Policy Dir, Congressman Meehan	<input checked="" type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAX

16. Specific lobbying issues

Issues related to health savings accounts, the health insurance tax and other taxes included in the Affordable Care Act.
S. 1859, the Healthcare Tax Relief Act of 2017
H.R. 95, Making Further Continuing Appropriations for the fiscal year ending September 30, 2018
H.R. 4620, the Protecting Families and Small Business Act of 2018
H.R. 5138, the Bipartisan HSA Improvement Act of 2018

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Shannon	Penberthy			<input type="checkbox"/>
Elizabeth	Brooks			<input type="checkbox"/>
Tegan	Gelfand			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

Issues related to prescription drug abuse, Medicare Part D, and Medicare payment for home infusion.

S.413/H.R. 1039, The Improving Transparency and Accuracy in Medicare Part D Spending Act of 2017
H.R.1316, The Prescription Drug Price Transparency Act of 2017
S. 2460/H.R. 3528, The Every Prescription Conveyed Safely Act of 2017
S. 1738/H.R. 3163, The Medicare Home Infusion Therapy Act of 2017
H.R. 3178, The Medicare Part B Improvement Act of 2017
S. 2553, The Know the Lowest Price Act of 2018
H.R. 4841, The Standardizing Electronic Prior Authorization for Safe Prescribing Act

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB)

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Elizabeth	Brooks			<input type="checkbox"/>
Shannon	Penberthy			<input type="checkbox"/>
Ashli	Palmer			<input type="checkbox"/>
Amy	Rosenbaum		Sr Advisor/Deputy Advisor to the President; Policy Director, Office of Speaker/Minority Leader; Sr Advisor, Committee on Education & the Workforce; Research Dir, Asst to Minority Leader; Staff Asst, Leg Asst, Leg Dir, Policy Dir, Congressman Meehan	<input checked="" type="checkbox"/>
Tegan	Gelfand			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code VET

16. Specific lobbying issues

Issues related to veterans access to healthcare and VA CHOICE Act reauthorization. S. 1526, The Veterans Access to Community Care Act of 2017 H.R. 4242, The VA Care in the Community Act S. 2184, The Veterans Community Care and Access Act
--

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
--

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Shannon	Penberthy			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

--

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

Issues related to implementation and changes to the Affordable Care Act.

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Elizabeth	Brooks			<input type="checkbox"/>
Shannon	Penberthy			<input type="checkbox"/>
Ashli	Palmer			<input type="checkbox"/>
Amy	Rosenbaum		Sr Advisor/Deputy Advisor to the President; Policy Director, Office of Speaker/Minority Leader; Sr Advisor, Committee on Education & the Workforce; Research Dir, Asst to Minority Leader; Staff Asst, Leg Asst, Leg Dir, Policy Dir, Congressman Meehan	<input checked="" type="checkbox"/>
Tegan	Gelfand			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code LBR

16. Specific lobbying issues

Issues related to CVS Health announced merger with Aetna.

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Shannon	Penberthy			<input type="checkbox"/>
Melissa	Schulman			<input type="checkbox"/>
Elizabeth	Brooks			<input type="checkbox"/>
Ashli	Palmer			<input type="checkbox"/>
Tegan	Gelfand			<input type="checkbox"/>
Amy	Rosenbaum		Sr Advisor/Deputy Advisor to the President; Policy Director, Office of Speaker/Minority Leader; Sr Advisor, Committee on Education & the Workforce; Research Dir, Asst to Minority Leader; Staff Asst, Leg Asst, Leg Dir, Policy Dir, Congressman Meehan	<input checked="" type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CPT

16. Specific lobbying issues

Issues related to barriers to generic drug and biosimilar market entry including pay-for-delay and REMS.

S. 124, The Preserve Access to Affordable Generics Act of 2017
 S. 771/H.R. 1776, The Improving Access to Affordable Prescription Drugs Act of 2017
 H.R. 2051, The Fair Access for Safe and Timely Generics Act of 2017
 S. 974/H.R. 2212, The Creating and Restoring Equal Access to Equivalent Samples Act of 2017

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Shannon	Penberthy			<input type="checkbox"/>
Melissa	Schulman			<input type="checkbox"/>
Elizabeth	Brooks			<input type="checkbox"/>
Ashli	Palmer			<input type="checkbox"/>
Amy	Rosenbaum		Sr Advisor/Deputy Advisor to the President; Policy Director, Office of Speaker/Minority Leader; Sr Advisor, Committee on Education & the Workforce; Research Dir, Asst to Minority Leader; Staff Asst, Leg Asst, Leg Dir, Policy Dir, Congressman Meehan	<input checked="" type="checkbox"/>
Tegan	Gelfand			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

Address _____
 City _____ State _____ Zip Code _____ Country _____

21. Client new principal place of business (if different than line 20)

City _____ State _____ Zip Code _____ Country _____

22. New General description of client's business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

First Name	Last Name	Suffix	First Name	Last Name	Suffix
------------	-----------	--------	------------	-----------	--------

ISSUE UPDATE

24. General lobbying issue that no longer pertains

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

Name	Address				Principal Place of Business (city and state or country)
	Street Address	State/Province	Zip	Country	
	City				

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities:

Name	Address			Principal place of business (city and state or country)	Amount of contribution for lobbying activities	Ownership percentage in client
	Street Address	State/Province	Country			
	City					

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

Clerk of the House of Representatives Legislative Resource Center 135 Cannon Building Washington, DC 20515 http://lobbyingdisclosure.house.gov	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510 http://www.senate.gov/lobby
--	---

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name <input checked="" type="checkbox"/> Organization/Lobbying Firm <input type="checkbox"/> Self Employed Individual CVS Health	
2. Address Address1 <u>1275 Pennsylvania Avenue, NW</u> Address2 <u>Suite 700</u> City <u>Washington</u> State <u>DC</u> Zip Code <u>20004</u> Country <u>USA</u>	
3. Principal place of business (if different than line 2) City <u>Woonsocket</u> State <u>RI</u> Zip Code <u>02895</u> Country <u>USA</u>	
4a. Contact Name <u>Mrs. Shannon Penberthy</u>	b. Telephone Number <u>2027723504</u> c. E-mail <u>shannon.penberthy@cvshealth.com</u>
5. Senate ID# <u>302778-12</u>	
7. Client Name <input checked="" type="checkbox"/> Self <input type="checkbox"/> Check if client is a state or local government or instrumentality CVS Health	6. House ID# <u>394420000</u>

TYPE OF REPORT 8. Year 2018 Q1 (1/1 - 3/31) Q2 (4/1 - 6/30) Q3 (7/1 - 9/30) Q4 (10/1 - 12/31)

9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report Termination Date _____ 11. No Lobbying Issue Activity

INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13	
<p>12. Lobbying</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$5,000 <input type="checkbox"/></p> <p>\$5,000 or more <input type="checkbox"/> \$ _____</p> <p>Provide a good faith estimate, rounded to the nearest \$10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p>13. Organizations</p> <p>EXPENSE relating to lobbying activities for this reporting period were:</p> <p>Less than \$5,000 <input type="checkbox"/></p> <p>\$5,000 or more <input checked="" type="checkbox"/> \$ <u>1,300,000.00</u></p> <p>14. REPORTING Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definitions only</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code</p>

Signature Digitally Signed By: Shannon Penberthy Date _____

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code PHA

16. Specific lobbying issues

Issues related to prescription drug abuse, medication adherence, drug price transparency, and gag clauses.

H.R. 1316, The Prescription Drug Price Transparency Act of 2017
 S. 778/H.R. 1854, The Prescription Drug Monitoring Act of 2017
 S. 2460/H.R. 3528, The Every Prescription Conveyed Securely Act of 2017
 S. 892/H.R. 4408, The Opioid Addiction Prevention Act of 2017
 S. 2456/H.R. 5311, The CARA 2.0 Act of 2018
 S. 2553/H.R. 6144, The Know the Lowest Price Act of 2018
 S. 2554/H.R. 6143, The Patient Right to Know Drug Prices Act of 2018
 H.R. 5343, The Prescription Transparency Act of 2018
 H.R. 6, The SUPPORT for Patients and Communities Act of 2018
 H.R. 6133, The Informing Opioid Prescribing Through Evidence-Based Guidelines Act of 2018

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, White House Office, Health & Human Services - Dept of (HHS)

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Melissa	Schulman			<input type="checkbox"/>
Elizabeth	Brooks			<input type="checkbox"/>
Shannon	Penberthy			<input type="checkbox"/>
Ashli	Palmer			<input type="checkbox"/>
Tegan	Gelfand			<input type="checkbox"/>
Amy	Rosenbaum			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAX

16. Specific lobbying issues

Issues related to health savings accounts, the health insurance tax and other taxes included in the Affordable Care Act.
H.R. 5138, The Bipartisan HSA Improvement Act of 2018
H.R. 5963, To delay the reimposition of the annual fee on health insurance providers until after 2020

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Shannon	Penberthy			<input type="checkbox"/>
Tegan	Gelfand			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

Issues related to prescription drug abuse and Medicare Part D.

S.413/H.R. 1039, The Improving Transparency and Accuracy in Medicare Part D Spending Act of 2017
 H.R.1316, The Prescription Drug Price Transparency Act of 2017
 S. 2460/H.R. 3528, The Every Prescription Conveyed Securely Act of 2017
 S. 2553/H.R. 6144, The Know the Lowest Price Act of 2018
 H.R. 4841, The Standardizing Electronic Prior Authorization for Safe Prescribing Act
 H.R. 5958, The Phair Pricing Act of 2018

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Elizabeth	Brooks			<input type="checkbox"/>
Shannon	Penberthy			<input type="checkbox"/>
Ashli	Palmer			<input type="checkbox"/>
Amy	Rosenbaum			<input type="checkbox"/>
Tegan	Gelfand			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code VET

16. Specific lobbying issues

Issues related to veterans access to healthcare and VA CHOICE Act reauthorization.
S. 2372, The VA MISSION Act

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Shannon	Penberthy			<input type="checkbox"/>
Amy	Rosenbaum			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

Issues related to implementation and changes to the Affordable Care Act.

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Elizabeth	Brooks			<input type="checkbox"/>
Shannon	Penberthy			<input type="checkbox"/>
Ashli	Palmer			<input type="checkbox"/>
Amy	Rosenbaum			<input type="checkbox"/>
Tegan	Gelfand			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code LBR

16. Specific lobbying issues

Issues related to CVS Health announced merger with Aetna.

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Shannon	Penberthy			<input type="checkbox"/>
Melissa	Schulman			<input type="checkbox"/>
Elizabeth	Brooks			<input type="checkbox"/>
Ashli	Palmer			<input type="checkbox"/>
Tegan	Gelfand			<input type="checkbox"/>
Amy	Rosenbaum			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CPT

16. Specific lobbying issues

Issues related to barriers to generic drug and biosimilar market entry including pay-for-delay and REMS.
 S. 124, The Preserve Access to Affordable Generics Act of 2017
 S.771/H.R. 1776, The Improving Access to Affordable Prescription Drugs Act of 2017
 H.R. 2051, The Fair Access for Safe and Timely Generics Act of 2017
 S. 974/H.R. 2212, The Creating and Restoring Equal Access to Equivalent Samples Act of 2017

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Shannon	Penberthy			<input type="checkbox"/>
Melissa	Schulman			<input type="checkbox"/>
Elizabeth	Brooks			<input type="checkbox"/>
Ashli	Palmer			<input type="checkbox"/>
Amy	Rosenbaum			<input type="checkbox"/>
Tegan	Gelfand			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

Address _____
 City _____ State _____ Zip Code _____ Country _____

21. Client new principal place of business (if different than line 20)

City _____ State _____ Zip Code _____ Country _____

22. New General description of client's business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

First Name	Last Name	Suffix	First Name	Last Name	Suffix
------------	-----------	--------	------------	-----------	--------

ISSUE UPDATE

24. General lobbying issue that no longer pertains

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

Name	Address				Principal Place of Business (city and state or country)
	Street Address	State/Province	Zip	Country	

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities:

Name	Address			Principal place of business (city and state or country)	Amount of contribution for lobbying activities	Ownership percentage in client
	Street Address	State/Province	Country			

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

Clerk of the House of Representatives Legislative Resource Center 135 Cannon Building Washington, DC 20515 http://lobbyingdisclosure.house.gov	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510 http://www.senate.gov/lobby
--	---

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name <input checked="" type="checkbox"/> Organization/Lobbying Firm <input type="checkbox"/> Self Employed Individual CVS Health	
2. Address Address1 <u>1275 Pennsylvania Avenue, NW</u> Address2 <u>Suite 700</u> City <u>Washington</u> State <u>DC</u> Zip Code <u>20004</u> Country <u>USA</u>	
3. Principal place of business (if different than line 2) City <u>Woonsocket</u> State <u>RI</u> Zip Code <u>02895</u> Country <u>USA</u>	
4a. Contact Name Mrs. <u>Shannon Penberthy</u>	b. Telephone Number <u>2027723504</u>
c. E-mail <u>shannon.penberthy@cvshealth.com</u>	
5. Senate ID# <u>302778-12</u>	
7. Client Name <input checked="" type="checkbox"/> Self <input type="checkbox"/> Check if client is a state or local government or instrumentality CVS Health	6. House ID# <u>394420000</u>

TYPE OF REPORT 8. Year 2018 Q1 (1/1 - 3/31) Q2 (4/1 - 6/30) Q3 (7/1 - 9/30) Q4 (10/1 - 12/31)

9. Check if this filing amends a previously filed version of this report
 10. Check if this is a Termination Report Termination Date _____ 11. No Lobbying Issue Activity

INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13	
<p align="center">12. Lobbying</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$5,000 <input type="checkbox"/></p> <p>\$5,000 or more <input type="checkbox"/> \$ _____</p> <p>Provide a good faith estimate, rounded to the nearest \$10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p align="center">13. Organizations</p> <p>EXPENSE relating to lobbying activities for this reporting period were:</p> <p>Less than \$5,000 <input type="checkbox"/></p> <p>\$5,000 or more <input checked="" type="checkbox"/> \$ <u>1,442,000.00</u></p> <p>14. REPORTING Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definitions only</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code</p>

Signature Digitally Signed By: Shannon Penberthy **Date** _____

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code PHA

16. Specific lobbying issues

Issues related to prescription drug abuse, medication adherence, drug price transparency, and gag clauses.

H.R. 1316, The Prescription Drug Price Transparency Act of 2017
 S. 2553/H.R. 6144, The Know the Lowest Price Act of 2018
 S. 2554/H.R. 6143, The Patient Right to Know Drug Prices Act of 2018
 H.R. 5343, The Prescription Transparency Act of 2018
 H.R. 6, The SUPPORT for Patients and Communities Act of 2018
 S. 2680, The Opioids Crisis Response Act

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, White House Office, Health & Human Services - Dept of (HHS)

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Elizabeth	Brooks			<input type="checkbox"/>
Shannon	Penberthy			<input type="checkbox"/>
Ashli	Palmer			<input type="checkbox"/>
Tegan	Gelfand			<input type="checkbox"/>
Amy	Rosenbaum			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAX

16. Specific lobbying issues

Issues related to health savings accounts, the health insurance tax and other taxes included in the Affordable Care Act.
H.R. 5138, The Bipartisan HSA Improvement Act of 2018
H.R. 6199, Restoring Access to Medication and Modernizing Health Savings Accounts Act of 2018
H.R. 6311, Increasing Access to Lower Premium Plans and Expanding Health Savings Accounts Act of 2018

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Shannon	Penberthy			<input type="checkbox"/>
Tegan	Gelfand			<input type="checkbox"/>
Ashli	Palmer			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

Issues related to prescription drug abuse and Medicare Part D.

S.413/H.R. 1039, The Improving Transparency and Accuracy in Medicare Part D Spending Act of 2017
 H.R.1316, The Prescription Drug Price Transparency Act of 2017
 S. 2553/H.R. 6144, The Know the Lowest Price Act of 2018
 H.R. 5958, The Phair Pricing Act of 2018
 H.R. 4143/S. 2065, The Dialysis PATIENTS Demonstration Act of 2017

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Elizabeth	Brooks			<input type="checkbox"/>
Shannon	Penberthy			<input type="checkbox"/>
Ashli	Palmer			<input type="checkbox"/>
Amy	Rosenbaum			<input type="checkbox"/>
Tegan	Gelfand			<input type="checkbox"/>
Melissa	Schulman			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code VET

16. Specific lobbying issues

Issues related to veterans access to healthcare.

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Veterans Affairs - Dept of (VA)

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Shannon	Penberthy			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

Issues related to implementation and changes to the Affordable Care Act.

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Elizabeth	Brooks			<input type="checkbox"/>
Shannon	Penberthy			<input type="checkbox"/>
Ashli	Palmer			<input type="checkbox"/>
Amy	Rosenbaum			<input type="checkbox"/>
Tegan	Gelfand			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code LBR

16. Specific lobbying issues

Issues related to CVS Health announced merger with Aetna.

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Shannon	Penberthy			<input type="checkbox"/>
Melissa	Schulman			<input type="checkbox"/>
Elizabeth	Brooks			<input type="checkbox"/>
Ashli	Palmer			<input type="checkbox"/>
Tegan	Gelfand			<input type="checkbox"/>
Amy	Rosenbaum			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CPT

16. Specific lobbying issues

Issues related to barriers to generic drug and biosimilar market entry including pay-for-delay and REMS.

S. 124, The Preserve Access to Affordable Generics Act of 2017
 S.771/H.R. 1776, The Improving Access to Affordable Prescription Drugs Act of 2017
 H.R. 2051, The Fair Access for Safe and Timely Generics Act of 2017
 S. 974/H.R. 2212, The Creating and Restoring Equal Access to Equivalent Samples Act of 2017

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Shannon	Penberthy			<input type="checkbox"/>
Melissa	Schulman			<input type="checkbox"/>
Elizabeth	Brooks			<input type="checkbox"/>
Ashli	Palmer			<input type="checkbox"/>
Amy	Rosenbaum			<input type="checkbox"/>
Tegan	Gelfand			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

Address _____
 City _____ State _____ Zip Code _____ Country _____

21. Client new principal place of business (if different than line 20)

City _____ State _____ Zip Code _____ Country _____

22. New General description of client's business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

First Name	Last Name	Suffix	First Name	Last Name	Suffix
------------	-----------	--------	------------	-----------	--------

ISSUE UPDATE

24. General lobbying issue that no longer pertains

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

Name	Address				Principal Place of Business (city and state or country)
	Street Address	State/Province	Zip	Country	

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities:

Name	Address			Principal place of business (city and state or country)	Amount of contribution for lobbying activities	Ownership percentage in client
	Street Address	State/Province	Country			

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization

Clerk of the House of Representatives Legislative Resource Center 135 Cannon Building Washington, DC 20515 http://lobbyingdisclosure.house.gov	Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510 http://www.senate.gov/lobby
--	---

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name <input checked="" type="checkbox"/> Organization/Lobbying Firm <input type="checkbox"/> Self Employed Individual CVS Health	
2. Address Address1 <u>1275 Pennsylvania Avenue, NW</u> Address2 <u>Suite 700</u> City <u>Washington</u> State <u>DC</u> Zip Code <u>20004</u> Country <u>USA</u>	
3. Principal place of business (if different than line 2) City <u>Woonsocket</u> State <u>RI</u> Zip Code <u>02895</u> Country <u>USA</u>	
4a. Contact Name <u>Mrs. Shannon Penberthy</u>	b. Telephone Number <u>2027723504</u> c. E-mail <u>shannon.penberthy@cvshealth.com</u>
5. Senate ID# <u>302778-12</u>	
7. Client Name <input checked="" type="checkbox"/> Self <input type="checkbox"/> Check if client is a state or local government or instrumentality CVS Health	6. House ID# <u>394420000</u>

TYPE OF REPORT 8. Year 2018 Q1 (1/1 - 3/31) Q2 (4/1 - 6/30) Q3 (7/1 - 9/30) Q4 (10/1 - 12/31)

9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report Termination Date _____ 11. No Lobbying Issue Activity

INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13	
<p>12. Lobbying</p> <p>INCOME relating to lobbying activities for this reporting period was:</p> <p>Less than \$5,000 <input type="checkbox"/></p> <p>\$5,000 or more <input type="checkbox"/> \$ _____</p> <p>Provide a good faith estimate, rounded to the nearest \$10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).</p>	<p>13. Organizations</p> <p>EXPENSE relating to lobbying activities for this reporting period were:</p> <p>Less than \$5,000 <input type="checkbox"/></p> <p>\$5,000 or more <input checked="" type="checkbox"/> \$ <u>1,993,000.00</u></p> <p>14. REPORTING Check box to indicate expense accounting method. See instructions for description of options.</p> <p><input checked="" type="checkbox"/> Method A. Reporting amounts using LDA definitions only</p> <p><input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code</p> <p><input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code</p>

Signature Digitally Signed By: Shannon Penberthy Date _____

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code PHA

16. Specific lobbying issues

Issues related to prescription drug abuse, medication adherence, and drug price transparency.

H.R. 1316, The Prescription Drug Price Transparency Act of 2017
H.R. 5343, The Prescription Transparency Act of 2018
H.R. 6, The SUPPORT for Patients and Communities Act of 2018

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, White House Office, Health & Human Services - Dept of (HHS)

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Elizabeth	Brooks			<input type="checkbox"/>
Shannon	Penberthy			<input type="checkbox"/>
Ashli	Palmer			<input type="checkbox"/>
Tegan	Gelfand			<input type="checkbox"/>
Amy	Rosenbaum			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAX

16. Specific lobbying issues

Issues related to health savings accounts, the health insurance tax, and other taxes included in the Affordable Care Act.
 H.R. 5138, The Bipartisan HSA Improvement Act of 2018
 H.R. 6199, Restoring Access to Medication and Modernizing Health Savings Accounts Act of 2018
 H.R. 6311, Increasing Access to Lower Premium Plans and Expanding Health Savings Accounts Act of 2018

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Shannon	Penberthy			<input type="checkbox"/>
Tegan	Gelfand			<input type="checkbox"/>
Amy	Rosenbaum			<input type="checkbox"/>
Melissa	Schulman			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM

16. Specific lobbying issues

Issues related to prescription drug abuse and Medicare Part D.

S.413/H.R. 1039, The Improving Transparency and Accuracy in Medicare Part D Spending Act of 2017
 H.R.1316, The Prescription Drug Price Transparency Act of 2017
 H.R. 5958, The Phair Pricing Act of 2018
 H.R. 4143/S. 2065, The Dialysis PATIENTS Demonstration Act of 2017

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Elizabeth	Brooks			<input type="checkbox"/>
Shannon	Penberthy			<input type="checkbox"/>
Ashli	Palmer			<input type="checkbox"/>
Amy	Rosenbaum			<input type="checkbox"/>
Tegan	Gelfand			<input type="checkbox"/>
Melissa	Schulman			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code VET

16. Specific lobbying issues

Issues related to veterans access to healthcare.

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Veterans Affairs - Dept of (VA)

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Shannon	Penberthy			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

Issues related to implementation and changes to the Affordable Care Act.

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Elizabeth	Brooks			<input type="checkbox"/>
Shannon	Penberthy			<input type="checkbox"/>
Ashli	Palmer			<input type="checkbox"/>
Amy	Rosenbaum			<input type="checkbox"/>
Tegan	Gelfand			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code LBR

16. Specific lobbying issues

Issues related to CVS Health announced merger with Aetna.

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Shannon	Penberthy			<input type="checkbox"/>
Melissa	Schulman			<input type="checkbox"/>
Elizabeth	Brooks			<input type="checkbox"/>
Ashli	Palmer			<input type="checkbox"/>
Tegan	Gelfand			<input type="checkbox"/>
Amy	Rosenbaum			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CPT

16. Specific lobbying issues

Issues related to barriers to generic drug and biosimilar market entry including pay-for-delay and REMS.

S. 124, The Preserve Access to Affordable Generics Act of 2017
 S.771/H.R. 1776, The Improving Access to Affordable Prescription Drugs Act of 2017
 H.R. 2051, The Fair Access for Safe and Timely Generics Act of 2017
 S. 974/H.R. 2212, The Creating and Restoring Equal Access to Equivalent Samples Act of 2017

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS)

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Shannon	Penberthy			<input type="checkbox"/>
Melissa	Schulman			<input type="checkbox"/>
Elizabeth	Brooks			<input type="checkbox"/>
Ashli	Palmer			<input type="checkbox"/>
Amy	Rosenbaum			<input type="checkbox"/>
Tegan	Gelfand			<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Information Update Page - Complete ONLY where registration information has changed.

20. Client new address

Address _____
 City _____ State _____ Zip Code _____ Country _____

21. Client new principal place of business (if different than line 20)

City _____ State _____ Zip Code _____ Country _____

22. New General description of client's business or activities

LOBBYIST UPDATE

23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client

First Name	Last Name	Suffix	First Name	Last Name	Suffix
1 Ashli	Palmer		2		

ISSUE UPDATE

24. General lobbying issue that no longer pertains

AFFILIATED ORGANIZATIONS

25. Add the following affiliated organization(s)

Internet Address:

Name	Address				Principal Place of Business (city and state or country)
	Street Address	State/Province	Zip	Country	
	City				

26. Name of each previously reported organization that is no longer affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities:

Name	Address			Principal place of business (city and state or country)	Amount of contribution for lobbying activities	Ownership percentage in client
	Street Address	State/Province	Country			
	City					

28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization